Literature DB >> 34861373

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.

S Popat1, P Baas2, C Faivre-Finn3, N Girard4, A G Nicholson5, A K Nowak6, I Opitz7, A Scherpereel8, M Reck9.   

Abstract

Entities:  

Keywords:  clinical practice guideline; diagnosis; follow-up; malignant pleural mesothelioma; treatment

Mesh：

Year:  2021        PMID： 34861373     DOI： 10.1016/j.annonc.2021.11.005

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  12 in total

Review 1.  Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).

Authors:  Erika Rijavec; Federica Biello; Giulia Barletta; Chiara Dellepiane; Carlo Genova
Journal:  Mol Clin Oncol       Date:  2022-02-22

2.  Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold.

Authors:  Riccardo Orlandi; Francesca Bono; Diego Luigi Cortinovis; Giuseppe Cardillo; Ugo Cioffi; Angelo Guttadauro; Emanuele Pirondini; Stefania Canova; Enrico Mario Cassina; Federico Raveglia
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

3.  A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study.

Authors:  Giovanni Vicidomini; Carminia Maria Della Corte; Antonio Noro; Raimondo Di Liello; Salvatore Cappabianca; Alfonso Fiorelli; Valerio Nardone; Gaetana Messina; Giuseppe Viscardi; Angelo Sangiovanni; Riccardo Monti; Marina Accardo; Floriana Morgillo; Fortunato Ciardiello; Renato Franco; Mario Santini
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

Review 4.  Treatment of Patients with Malignant Peritoneal Mesothelioma.

Authors:  Claire Y Li; Timothy Kennedy; Henry Richard Alexander
Journal:  J Clin Med       Date:  2022-03-29       Impact factor: 4.241

Review 5.  Current Management and Future Perspective in Pleural Mesothelioma.

Authors:  Rajiv Shah; Laura V Klotz; Julia Glade
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

6.  ER Stress Response and Induction of Apoptosis in Malignant Pleural Mesothelioma: The Achilles Heel Targeted by the Anticancer Ruthenium Drug BOLD-100.

Authors:  Elia Ranzato; Gregorio Bonsignore; Simona Martinotti
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

7.  BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation.

Authors:  Nguyen Truong Duc Hoang; Ghmkin Hassan; Tomoya Suehiro; Yuichi Mine; Tohru Matsuki; Makiko Fujii
Journal:  BMC Cancer       Date:  2022-09-15       Impact factor: 4.638

8.  Editorial: Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models.

Authors:  Sze-Kwan Lam; Steven Eugene Mutsaers
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

9.  Clinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion.

Authors:  Guan-Ying Ma; Shuai Shi; Ping Wang; Xing-Guang Wang; Zhi-Gang Zhang
Journal:  Biomed Rep       Date:  2022-06-07

10.  Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma.

Authors:  Liu Yang; Xueqiong Cao; Na Li; Bin Zheng; Maobai Liu; Hongfu Cai
Journal:  Ther Adv Med Oncol       Date:  2022-08-03       Impact factor: 5.485
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.